文献速递消化系统肿瘤

仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌的Ib期研究

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
PubMed 文献 · J Clin Oncol · 2020-07-27

这项开放标签多中心Ib期研究评估仑伐替尼联合帕博利珠单抗治疗不可切除肝细胞癌,共纳入104例患者,其中100例为一线治疗。确认的客观缓解率按mRECIST为46.0%、按RECIST v1.1为36.0%,中位总生存为22个月,≥3级治疗相关不良事件发生率为67%。

要点

  • 一线不可切除肝细胞癌中联合方案确认ORR按mRECIST达46.0%。
  • 中位总生存为22个月,中位无进展生存按mRECIST为9.3个月。
  • ≥3级治疗相关不良事件发生率为67%,未发现新的安全信号。

核心结论

  • 仑伐替尼联合帕博利珠单抗在不可切除肝细胞癌中显示出有前景的抗肿瘤活性。
  • 毒性可控,未发现非预期的安全信号。

研究设计与样本

  • 开放标签、多中心Ib期研究,包含剂量限制性毒性阶段和扩展阶段(一线患者)。
  • 共纳入104例不可切除肝细胞癌患者;扩展阶段100例患者既往未接受全身治疗,BCLC B期29例、C期71例。
  • 给药方案为仑伐替尼口服每日一次(体重≥60 kg 12 mg;<60 kg 8 mg)联合帕博利珠单抗200 mg静脉给药,每21天周期第1天。
  • 主要目标:剂量限制性毒性阶段为安全性/耐受性;扩展阶段为独立影像学评审按mRECIST和RECIST v1.1评估的客观缓解率和缓解持续时间。

主要发现

  • 剂量限制性毒性阶段6例患者未报告剂量限制性毒性。
  • 数据截止时37%患者仍在治疗,中位随访时间10.6个月(95% CI,9.2至11.5个月)。
  • 独立影像学评审确认的客观缓解率按mRECIST为46.0%(95% CI,36.0%至56.3%),按RECIST v1.1为36.0%(95% CI,26.6%至46.2%)。
  • 中位缓解持续时间按mRECIST为8.6个月(95% CI,6.9个月至不可估计),按RECIST v1.1为12.6个月(95% CI,6.9个月至不可估计)。
  • 独立影像学评审中位无进展生存按mRECIST为9.3个月、按RECIST v1.1为8.6个月;中位总生存为22个月。

临床怎么用

  • 该联合方案可作为不可切除肝细胞癌一线治疗的候选选择之一,但需结合患者体能状态与安全性管理。
  • 治疗期间应重点监测≥3级治疗相关不良事件,并按照mRECIST与RECIST v1.1分别评估疗效。

局限性

  • 为单臂Ib期研究,未设对照,样本量有限(共104例)。
  • 随访时间有限,中位随访10.6个月,部分缓解持续时间数据尚未达到。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The immunomodulatory effect of lenvatinib (a multikinase inhibitor) on tumor microenvironments may contribute to antitumor activity when combined with programmed death receptor-1 (PD-1) signaling inhibitors in hepatocellular carcinoma (HCC). We report results from a phase Ib study of lenvatinib plus pembrolizumab (an anti-PD-1 antibody) in unresectable HCC (uHCC). PATIENTS AND METHODS: In this open-label multicenter study, patients with uHCC received lenvatinib (bodyweight ≥ 60 kg, 12 mg; < 60 kg, 8 mg) orally daily and pembrolizumab 200 mg intravenously on day 1 of a 21-day cycle. The study included a dose-limiting toxicity (DLT) phase and an expansion phase (first-line patients). Primary objectives were safety/tolerability (DLT phase), and objective response rate (ORR) and duration of response (DOR) by modified RECIST (mRECIST) and RECIST version 1.1 (v1.1) per independent imaging review (IIR; expansion phase). RESULTS: A total of 104 patients were enrolled. No DLTs were reported (n = 6) in the DLT phase; 100 patients (expansion phase; included n = 2 from DLT phase) had received no prior systemic therapy and had Barcelona Clinic Liver Cancer stage B (n = 29) or C disease (n = 71). At data cutoff, 37% of patients remained on treatment. Median duration of follow-up was 10.6 months (95% CI, 9.2 to 11.5 months). Confirmed ORRs by IIR were 46.0% (95% CI, 36.0% to 56.3%) per mRECIST and 36.0% (95% CI, 26.6% to 46.2%) per RECIST v1.1. Median DORs by IIR were 8.6 months (95% CI, 6.9 months to not estimable [NE]) per mRECIST and 12.6 months (95% CI, 6.9 months to NE) per RECIST v1.1. Median progression-free survival by IIR was 9.3 months per mRECIST and 8.6 months per RECIST v1.1. Median overall survival was 22 months. Grade ≥ 3 treatment-related adverse events occurred in 67% (grade 5, 3%) of patients. No new safety signals were identified. CONCLUSION: Lenvatinib plus pembrolizumab has promising antitumor activity in uHCC. Toxicities were manageable, with no unexpected safety signals.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Finn RS, Ikeda M, Zhu AX, et al. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma. J Clin Oncol. 2020. PMID: 32716739. doi:10.1200/JCO.20.00808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。